United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - cefalexin - oral capsule - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - cefalexin - oral capsule - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ecuphar nv - cefalexin monohydrate - tablet - 250 mg/tablet - cefalexin

Ireland - English - HPRA (Health Products Regulatory Authority)

ecuphar nv - cefalexin monohydrate - tablet - 50 mg/tablet - cefalexin

Ireland - English - HPRA (Health Products Regulatory Authority)

ecuphar nv - cefalexin monohydrate - tablet - 500 mg/tablet - cefalexin

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cefalexin monohydrate (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; patent blue v; quinoline yellow; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cilex is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cilex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cefalexin monohydrate (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; patent blue v; quinoline yellow; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cilex is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cilex. renal function studies should be perfomed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - cefalexin monohydrate 262.9mg equivalent to 250 mg cefalexin anhydrous. - capsule - 250 mg - active: cefalexin monohydrate 262.9mg equivalent to 250 mg cefalexin anhydrous. excipient: hard gelatin capsules size "2" tekprint sw-9008 black ink magnesium stearate microcrystalline cellulose

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -